June 2007
Applied Clinical Trials;Jun2007, Vol. 16 Issue 6, p30
Academic Journal
The article offers news briefs related to clinical trials. Paris, France-based NicOx SA has begun its second Phase III naproxcinod trial to verify the effectiveness of the drug. Sydney, New South Wales-based Alchemia Lid. has completed its Phase II study comparing its product HyCAMP with irinotecan. Phosphagenics plans to start its Phase Ib clinical trial of TPM-02/Insulin gel.


Related Articles

  • Successful phase II efficacy results with NicOx compound in acute pain.  // PharmaWatch: Biotechnology;August 2003, Vol. 2 Issue 8, p10 

    Reports on the result of the clinical trial of NCX 701 by NicOx SA for pain management. Efficacy of NCX 701 to treat acute pain; Patients enrolled in the clinical study; Presentation of the clinical study of NCX 701.

  • Phosphagenics working on topical opioid patch.  // Australian Life Scientist;Mar/Apr2013, Vol. 10 Issue 2, p6 

    The article informs that Phosphagenics Ltd. has included an oxycodone-based patch designed for local pain relief in its pain patch portfolio and is also planning to start clinical trials of a similar version of the patch in the third quarter.

  • Clinic Roundup.  // BioWorld Today;3/ 1/2013, Vol. 24 Issue 40, p7 

    The article offers news briefs related to clinical drug studies including Alchemia Ltd.'s study of HA-Irinotecan in metastatic colorectal cancer patients, CytRx Corp.'s study of tamibarotene in advanced non-small-cell lung cancer, and Trophos SA's study of olesoxime in spinal muscular atrophy.

  • NicOx Shows Positive Data From 2nd Naproxcinod Trial. Etheridge, James // BioWorld International;9/17/2008, Vol. 13 Issue 38, p2 

    The article focuses on the positive results from NicOx SA's second Phase III trial of the drug, naproxcinod in the treatment of osteorarthritis of the knee of 1,020 patients. According to the test, there is reduction in systolic and diastolic blood pressure at weeks 13 and 26. This trial is the...

  • CLINIC ROUNDUP.  // BioWorld Today;4/4/2007, Vol. 18 Issue 65, p7 

    The article presents updates on clinical trials in the pharmaceutical and biotechnology industry. NanoBio Corp. has started enrolling patients in a phase II trial of NB-002 for fungal infection of the fingernail and toenail. NicOx SA has began the second pivotal phase II trial of naproxcinod for...

  • Pfizer Pullout Sends NicOx Shares Down.  // Bioworld Week;5/12/2008, Vol. 16 Issue 19, p3 

    The article reports on the downfall of NicOx SA's shares after its partner, Pfizer Inc., decided that the data from a U.S. Phase II trial in glaucoma and ocular hypertension were not strong enough to warrant an expanded Phase III test. The Phase II trial tested the safety and efficacy of various...

  • POSITIVE RESULTS FROM PHASE 1B OF OXYCODONE PATCH.  // Worldwide Biotech;Mar2010, Vol. 22 Issue 3, p1 

    The article reports on the positive results of the Phase 1B clinical study conducted by Phosphagenics Ltd. using its Targeted Penetration Matrix (TPMâ„¢) for the transdermal delivery of oxycodone. The trial has successfully demonstrated that daily application of a TPMâ„¢-oxycodone patch...

  • R&D Update.  // PharmaWatch: CNS;Nov2007, Vol. 6 Issue 11, p10 

    The article offers news briefs related to pharmaceutical industry worldwide in 2007. Adlea is a long-acting, non-opiate analgesic drug which designed for weeks to months pain relief in single local dose during the surgical procedure. Australian company Phosphagenics has received approval to...

  • Clinic Roundup.  // BioWorld Today;9/13/2011, Vol. 22 Issue 177, p4 

    This section offers news briefs concerning clinical trials within the U.S. biopharmaceutical industry. Alchemia Ltd. began recruitment for a Phase II trial of its HA-Irinotecan for the treatment of small-cell lung cancer. HemaQuest Pharmaceuticals Inc. completed enrollment in a Phase II study of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics